Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 15

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
The
CEO of the Company is also the CEO and chairman of Zander.

  Sublease     

On
January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“ BST”) whereby Regen Biopharma,
Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis
for $ 5,000

The
Company agreed that in addition to the base rent of $ 5,000

BST
Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

  Notes                       

The
Company had the following notes payable to related party transactions

  Notes                                                                                                                                        
  $ 73,303 lent to the Company by David Koos, the Company’s sole Board Member and Officer, is due and payable at the demand of the holder      
  Notes                                                                                                                                        
  $ 15,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of 10% per   
  $ 25,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of 10% per  
  $ 10,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on October 4, 2025 and bears simple interest at a rate of 10%   
  $ 4,700 lent to the Company by Zander Therapeutics, Inc. is due and payable on October 15, 2025 and bears simple interest at a rate of 10%   
  $ 4,500 lent to the Company by Zander Therapeutics, Inc. is due and payable on October 23, 2025 and bears simple interest at a rate of 10%   

  The                                                                                                                                
  Notes                                                                                                                              
  BST                                                                                                                                
  During                                                                                                                             
  During                                                                                                                             
  During                                                                                                                             
  BST                                                                                                                                

14. SUSBEQUENT EVENTS

The
Company assessed subsequent events through August 4, 2025, the date on which the financial statements became available for issuance.
The Company has determined that there are no subsequent events that require disclosure other than the following:

  On                                                                                                                                     
  July 28, 2025